sj-docx-2-tar-10.1177_17534666231214134 – Supplemental material for Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study

Supplemental material, sj-docx-2-tar-10.1177_17534666231214134 for Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study by Rongli Lu, Ying Li, Chengping Hu, Pinhua Pan, Qiaohong Zhao and Ruoxi He in Therapeutic Advances in Respiratory Disease</p

sj-docx-1-tar-10.1177_17534666231214134 – Supplemental material for Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study

Supplemental material, sj-docx-1-tar-10.1177_17534666231214134 for Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study by Rongli Lu, Ying Li, Chengping Hu, Pinhua Pan, Qiaohong Zhao and Ruoxi He in Therapeutic Advances in Respiratory Disease</p

Diagnostic Accuracy of Bronchodilator Response for Asthma in a Population of South China

Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides </p

Table_1_Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study.docx

ObjectiveStage III non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases. For this subset of patients, clinical management is still under debate and prognosis remains poor so far. In the present study, we aimed to evaluate the feasibility and safety of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in stage III NSCLC.MethodsA real-world prospective cohort study was performed in a single-center setting from April 2021 to May 2022. Patients who were diagnosed with resectable or potentially resectable stage IIIA–B NSCLC and received neoadjuvant chemoimmunotherapy followed by robotic-assisted thoracic surgery were enrolled. Pathological response to neoadjuvant chemoimmunotherapy, treatment-related adverse events, and surgical outcomes of these patients were evaluated.ResultsA total of 44 patients who underwent robotic-assisted thoracic surgery after three doses of neoadjuvant chemoimmunotherapy were included in this study. Of these, 36 of 44 (81.8%) patients had a major pathological response, and 26 (59.1%) had a pathological complete response based on pathological examination of surgical specimen. Eight patients (18.2%) suffered grade 3 treatment-related adverse events, including neutropenia (n = 4), increased aminotransferases (n = 3), anemia (n = 1), and cutaneous capillary endothelial proliferation (n = 1). Robotic-assisted thoracic surgery was performed subsequently, and R0 resection was achieved in all patients. Only two (4.5%) patients required conversion to thoracotomy. Surgical complications occurred in five (11.4%) patients, including air leak (n = 3), chylothorax (n = 2), and surgical site infection (n = 1). There was no re-surgery or postoperative mortality within 90 days.ConclusionRobotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy showed good feasibility and safety in stage III NSCLC. It was not associated with unexpected perioperative morbidity or mortality and may be a promising therapeutic option in stage III NSCLC. These results need further confirmation by more large-scale clinical trials.</p

Additional file 1 of Abnormal heart rate responses to exercise in non-severe COPD: relationship with pulmonary vascular volume and ventilatory efficiency

Supplementary Material

sj-docx-1-tar-10.1177_17534666231206249 – Supplemental material for Associations of medication regimen complexity with medication adherence and clinical outcomes in patients with chronic obstructive pulmonary disease: a prospective study

Supplemental material, sj-docx-1-tar-10.1177_17534666231206249 for Associations of medication regimen complexity with medication adherence and clinical outcomes in patients with chronic obstructive pulmonary disease: a prospective study by Ruoxi He, Ye Wang, Xiaoxia Ren, Ke Huang, Jieping Lei, Hongtao Niu, Wei Li, Fen Dong, Baicun Li, Ting Yang and Chen Wang in Therapeutic Advances in Respiratory Disease</p

MOESM4 of Variable DNA methylation of aging-related genes is associated with male COPD

Additional file 4. The expression of differentially expressed aging-related genes decreased with age. Non-smoking control samples showed a continues mRNA decrease in relation to age. Spearman’s correlation between mRNA level of aging-related genes (AREG, ATG3, E2F1, FOXO3, HDAC1, NUF2, TGFβ1 and TP53) and age is significant. Data are represented as scatter plots with linear fits. * p < 0.05; ** p < 0.0

MOESM2 of Variable DNA methylation of aging-related genes is associated with male COPD

Additional file 2. Flow chart of aging-related genes selection proces

MOESM1 of Variable DNA methylation of aging-related genes is associated with male COPD

Additional file 1. Primer sequence of aging-related genes for qPC

MOESM3 of Variable DNA methylation of aging-related genes is associated with male COPD

Additional file 3.Meta-analysis of 25 candidate aging-related genes in COPD group. p-value < 0.05 was considered as significan